# Intracranial Pressure Monitoring and Management

## Introduction

Intracranial pressure monitoring is a cornerstone of neurocritical care for patients with severe traumatic brain injury, subarachnoid hemorrhage, hydrocephalus, and other conditions causing intracranial hypertension. The Monro-Kellie doctrine states that the cranial vault is a fixed volume containing brain parenchyma at 80 percent, CSF at 10 percent, and blood at 10 percent. An increase in any one component must be compensated by a decrease in another, or ICP will rise.

## Physiology of ICP

### Normal Values and Waveforms

Normal ICP ranges from 5 to 15 mmHg in adults and 3 to 7 mmHg in children. Intracranial hypertension is defined as sustained ICP above 22 mmHg per Brain Trauma Foundation fourth edition guidelines. Cerebral perfusion pressure equals mean arterial pressure minus ICP, with a target of 60 to 70 mmHg. The ICP waveform contains three components: P1 (percussion wave from arterial pulsation), P2 (tidal wave reflecting brain compliance), and P3 (dicrotic wave from venous pulsation). When P2 exceeds P1, it indicates decreased intracranial compliance and impending decompensation.

### Compliance and Volume-Pressure Relationship

The pressure-volume curve demonstrates an exponential relationship with an initial flat portion representing compensatory reserve followed by a steep decompensation phase. Compensatory mechanisms include CSF displacement to the spinal subarachnoid space and reduction in cerebral venous blood volume. Once these reserves are exhausted, small volume increases cause dramatic ICP elevation. Cerebral autoregulation normally maintains constant cerebral blood flow over a mean arterial pressure range of 50 to 150 mmHg, but this mechanism is frequently impaired in the injured brain.

## ICP Monitoring Devices

### External Ventricular Drain

The EVD is the gold standard for ICP monitoring because it measures CSF pressure directly from the lateral ventricle and allows therapeutic CSF drainage. It is placed via a frontal approach at Kocher's point, located 1 centimeter anterior to the coronal suture at the mid-pupillary line. The zero reference point is set at the tragus, approximating the foramen of Monro. Complications include infection at 5 to 15 percent that increases with duration beyond 5 days, hemorrhage in 1 to 2 percent, and malposition.

### Intraparenchymal Monitors

These devices use fiber-optic technology such as the Camino or strain-gauge technology such as the Codman Microsensor. They are placed in brain parenchyma via a burr hole, typically in the right frontal region. They cannot be recalibrated after placement, and baseline drift is possible. They lack therapeutic drainage capability but have a lower infection rate than EVDs.

### Other Monitoring Modalities

Subdural and epidural monitors are less accurate and less commonly used. Lumbar drain ICP monitoring is contraindicated with mass lesions due to herniation risk. Non-invasive ICP estimation methods include optic nerve sheath diameter measurement on ultrasound, where greater than 5 millimeters suggests elevated ICP, and transcranial Doppler pulsatility index.

## Indications for ICP Monitoring

ICP monitoring is indicated in severe TBI with GCS 3 to 8 and an abnormal CT scan, and in severe TBI with normal CT if two or more of the following are present: age over 40, unilateral or bilateral motor posturing, or systolic blood pressure below 90 mmHg. Additional indications include subarachnoid hemorrhage with hydrocephalus or poor grade (Hunt-Hess IV-V), intracerebral hemorrhage with intraventricular extension and hydrocephalus, acute hepatic failure with cerebral edema, and post-craniotomy patients with concern for swelling.

## Stepwise Management of Intracranial Hypertension

| Tier | Intervention | Mechanism | Key Considerations |
|------|-------------|-----------|-------------------|
| **1** | HOB 30°, neutral head | Optimize venous drainage | First step; ensure no cervical collar obstruction |
| **1** | Sedation/analgesia | Reduce metabolic demand | Propofol, midazolam, fentanyl |
| **1** | CSF drainage (EVD) | Direct volume removal | Intermittent or continuous |
| **1** | Treat systemic factors | Remove ICP drivers | Fever, seizures, agitation, hypercarbia |
| **2** | Osmotherapy (mannitol) | Osmotic gradient reduces edema | 0.25-1 g/kg; keep osmolarity <320 |
| **2** | Osmotherapy (HTS) | Osmotic gradient reduces edema | 3-23.4%; target Na 145-155 |
| **2** | Mild hyperventilation | Vasoconstriction → ↓ CBV | PaCO2 30-35; temporary only |
| **2** | Neuromuscular blockade | Eliminate dyssynchrony | Monitor with TOF |
| **3** | Barbiturate coma | Maximal metabolic suppression | Pentobarbital; titrate to burst suppression |
| **3** | Decompressive craniectomy | Remove volume constraint | Flap >12��15 cm with duraplasty |
| **3** | Moderate hypothermia | ↓ Metabolic demand | 32-34°C; limited evidence, many complications |

### Tier 1 Interventions

First-line interventions include elevation of the head of bed to 30 degrees with maintenance of neutral head position to optimize venous drainage, sedation and analgesia with propofol, midazolam, or fentanyl to reduce metabolic demand and ICP, CSF drainage via EVD either intermittently or continuously, treatment of systemic factors including fever, seizures, agitation, hyponatremia, and hypercarbia, and avoidance of jugular venous compression from tight cervical collars or head rotation.

### Tier 2 Interventions

Second-line interventions include osmotherapy with either mannitol 20 percent at 0.25 to 1 gram per kilogram bolus, maintaining serum osmolarity below 320 mOsm/L, or hypertonic saline in concentrations of 3, 7.5, or 23.4 percent targeting sodium of 145 to 155 mEq/L. Mild hyperventilation targeting PaCO2 of 30 to 35 mmHg provides a temporary measure through vasoconstriction that reduces cerebral blood flow. Neuromuscular blockade eliminates ventilator dyssynchrony and reduces ICP.

### Tier 3 Interventions

Third-line interventions include barbiturate coma with pentobarbital loading at 5 to 10 milligrams per kilogram and maintenance at 1 to 3 milligrams per kilogram per hour, titrated to burst suppression on EEG. Decompressive craniectomy with a large bone flap removal greater than 12 by 15 centimeters and duraplasty represents the most aggressive surgical option. Moderate hypothermia at 32 to 34 degrees Celsius has limited evidence and significant systemic complications.

## Multimodal Neuromonitoring

Brain tissue oxygen monitoring targets PbtO2 above 20 mmHg and guides CPP optimization. Cerebral microdialysis measures the lactate-to-pyruvate ratio, with values above 40 indicating metabolic crisis. Jugular venous oximetry targets SjvO2 of 55 to 75 percent, with low values indicating ischemia. Continuous EEG detects non-convulsive seizures and guides barbiturate therapy. The BOOST-3 trial is evaluating PbtO2-guided therapy in TBI.

## Complications of ICP Monitoring

Infection is the most common complication, particularly with EVDs; antibiotic-impregnated catheters reduce this risk. Clinically significant hemorrhage occurs in 1 to 2 percent. Malposition of EVDs should be verified with CT, and non-functional drains should be replaced. CSF overdrainage can cause ventricular collapse and subdural hematoma.

## Clinical Pearls

The EVD remains the gold standard for ICP monitoring because it is the only device that allows both measurement and therapeutic CSF drainage. CPP-directed therapy must balance the risks of aggressive MAP augmentation, including ARDS and cardiac complications, against the risks of cerebral ischemia from inadequate perfusion. Hyperventilation should be used only as a temporary bridge measure for acute ICP crises; sustained hyperventilation causes vasoconstriction-mediated ischemia that worsens outcomes. An ICP waveform with P2 exceeding P1 is an early indicator of decreasing intracranial compliance and impending decompensation, signaling the need to escalate therapy before overt ICP crisis occurs.

## References
1. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the management of severe traumatic brain injury, Fourth Edition. Neurosurgery. 2017;80(1):6-15.
2. Chesnut RM, Temkin N, Carney N, et al. A trial of intracranial-pressure monitoring in traumatic brain injury. N Engl J Med. 2012;367(26):2471-2481.
3. Hawthorne C, Piper I. Monitoring of intracranial pressure in patients with traumatic brain injury. Front Neurol. 2014;5:121.
4. Le Roux P, Menon DK, Citerio G, et al. Consensus summary statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care. Neurocrit Care. 2014;21(Suppl 2):S1-26.